Gallbladder cancer (GBC) is a rare form of cancer with no signs or symptoms in the early stages. In the U.S., approximately 2 ...

A new blood test could change the outlook for one of the deadliest cancers—pancreatic cancer—by catching it much earlier than ever before. Researchers identified two previously unknown proteins in the ...

Spanish scientists say they have developed a potential breakthrough cure for treating pancreatic cancer, but the new therapy isn't ready for human use yet. Pancreatic cancer forms tumors in the ...

Prefer Newsweek on Google to see more of our trusted coverage when you search. A major medical breakthrough might have been achieved while researching an eventual cure for pancreatic cancer, as a new ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Cystic adenocarcinoma (marked in red) of the pancreas (outlined in green). Contrast‑enhanced ...

A quick and easy breath test could mean new hope in the early detection of pancreatic cancer, and medical experts say it could be the biggest breakthrough in the fight against the deadly disease in ...

In a randomized trial of patients with clinical T4a gastric cancer, laparoscopic distal gastrectomy (LDG) yielded similar rates of 30-day overall morbidity, 30-day mortality, and severe complications ...

Scientists have created a new antibody treatment that helps the immune system recognize and attack pancreatic cancer. Pancreatic cancer cells use a sugary "disguise" to trick the immune system into ...

THE SIX-MINUTE walking test offers an objective, low-cost assessment of postoperative recovery after pancreatic surgery. In a prospective cohort at 30 days, distance walked was significantly greater ...

A person's risk of pancreatic cancer might be tied to the microbes living in their mouths, a new study says. People have a more than tripled risk of pancreatic cancer if their mouths contain 27 types ...

JMT101 in combination with irinotecan and SG001 versus regorafenib in patients with metastatic colorectal adenocarcinoma (mCRC): Results of a randomized, controlled, open-label, phase II study.